July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its ...

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...

Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...

A new preclinical study in the journal Signal Transduction and Targeted Therapy describes a very promising therapeutic ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate ...

A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are most ...

Bayer announced two new collaborations, one with Kairos Pharma on a prostate cancer therapy and another with Henry Ford Health on wider research across several diseases. The Kairos Pharma partnership ...

Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is ...

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their ...

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit ...

ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights.